Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall SafiledCriticalAlmirall Sa
Priority to ARP150101657ApriorityCriticalpatent/AR100621A1/en
Publication of AR100621A1publicationCriticalpatent/AR100621A1/en
Compuesto, que es un inhibidor de fosfoinosítido 3-quinasa d o una sal farmacéuticamente aceptable y/o un solvato de los mismos, para uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos por administración oral. Reivindicación 11: El compuesto para uso según una cualquiera de las reivindicaciones precedentes, en donde el compuesto es LAS191954 o una sal farmacéuticamente aceptable y/o un solvato de los mismos y la enfermedad cutánea inmunoampollosa mediada por autoanticuerpos es pénfigo vulgar.Compound, which is a 3-kinase d phosphoinositide inhibitor or a pharmaceutically acceptable salt and / or solvate thereof, for use in the treatment of an autoantibody-mediated immunoampolose skin disease by oral administration. Claim 11: The compound for use according to any one of the preceding claims, wherein the compound is LAS191954 or a pharmaceutically acceptable salt and / or a solvate thereof and the autoantibody-mediated immunoampolous skin disease is pemphigus vulgaris.
Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
Compounds derived from unsaturated steroid lactones in position 7 (8) and their pharmaceutically acceptable salts and stereoisomers; pharmaceutical composition that includes them; and its use for the treatment of cancer.
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ACCOMPANIED BY DIABETES, INCLUDING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND A COMPOSITE PREPARATION INCLUDING THE SAME